View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These activites are not approved for AMA PRA Category 1 Credit™.

This activity is supported by educational grants from AbbVie, Ariad Pharmaceuticals, Inc., Celgene Corporation, Foundation Medicine, Inc., Gilead Sciences, Inc., Incyte, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pharmacyclics, Seattle Genetics, Inc., and Takeda Oncology.


Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma - PER Pulse™ Recap

PER Pulse Recap

PER Pulse™ Recap



1 of 3

Multiple Myeloma: Recap of Case-Based Discussion

Featuring key multiple myeloma (MM) expert Sagar Lonial, MD, FACP, this first of 3 PER Pulse™ Recaps from Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma summarizes expert perspectives on clinical vignettes of patients with MM:

  • The first clinical vignette involves a 54-year-old patient with symptomatic MM. Expert recommendation for this patient is the triplet regimen of bortezomib, lenalidomide, and dexamethasone (VRd), which demonstrated superior progression-free survival (PFS) and overall survival compared with Rd in the Southwest Oncology Group S0777 trial. Following induction with VRd, expert recommendation is autologous stem cell transplant (ASCT); following ASCT, maintenance therapy with lenalidomide is a standard of care, and it received approval from the US Food and Drug Administration in February 2017.
  • The second clinical vignette focuses on a 74-year-old patient with MM and a t(4;14) translocation. Expert recommendation is to assess this patient’s ability to undergo ASCT. If eligible for ASCT, maintenance bortezomib would also be offered due to the increased risk conferred by the translocation; if not fit for ASCT, this patient would be offered the RVD-lite regimen, which reduces the dosage and/or frequency of the agents compared with standard VRd.
  • The third clinical vignette involves a patient with MM who undergoes induction therapy with lenalidomide and dexamethasone, followed by ASCT and maintenance lenalidomide, and who experiences progression after 22 months. Expert recommendation is to explore a proteasome inhibitor‒based triplet regimen, as this patient had progressed on an immunomodulatory agent‒based course of therapy. One potential regimen is daratumumab, bortezomib, and dexamethasone (DVd), based on the CASTOR trial showing superior PFS compared with Vd.

For additional commentary about this topic and others, visit www.gotoper.com to access downloadable slides from the 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma.



2 of 3
PER Pulse™ Recap

Chronic Lymphocytic Leukemia: Recap of Case-Based Discussion

Featuring key chronic lymphocytic leukemia (CLL) expert Jennifer R. Brown, MD, PhD, this second of 3 PER Pulse™ Recaps from Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma summarizes expert perspective on a clinical vignette of a patient with CLL:

  • In the clinical vignette, a 62-year-old patient presents with CLL and unmutated IgHV gene. Expert recommendation for this patient is fludarabine, cyclophosphamide, and rituximab (FCR), although ibrutinib could be a consideration for a patient age ≥65 years. Patients with mutated IgHV genes, in particular, benefit from the FCR regimen; however, even patients with unmutated IgHV genes have a 12.8-year progression-free survival rate of 54%.
  • The patient in the vignette received ibrutinib as first-line therapy and progressed after approximately 3 years. Expert recommendation in this setting is venetoclax, based on a phase 2 trial of this agent in patients relapsing on ibrutinib or idelalisib; 70% of ibrutinib-pretreated patients responded. Idelalisib would be a second choice based on retrospective data showing a response rate of approximately 30% in patients failing ibrutinib.
  • In the event that the patient has del(17p) and disease progression on ibrutinib, expert recommendation would be venetoclax, which was approved in April 2016 for patients with CLL and del(17p) who have received ≥1 prior therapy.

For additional commentary about this topic and others, visit www.gotoper.com to access downloadable slides from the 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma.


3 of 3
PER Pulse™ Recap

Advances in Lymphomas and CAR-T Cell Therapy

Featuring key blood cancer experts Andre Goy, MD, MS, and Alfred L. Garfall, MD, MS, this third of 3 PER Pulse™ Recaps from Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma focuses on new therapeutic approaches for patients with lymphomas and the development of chimeric antigen receptor (CAR)-modified T cell therapy:

  • In patients with classical Hodgkin lymphoma (cHL), immune checkpoint inhibitors have become approved for patients with previously treated disease. Specifically, the anti-PD-1 antibody nivolumab received accelerated approval in May 2016 for the treatment of patients with cHL whose disease relapses or progresses after autologous stem cell transplantation and brentuximab vedotin. Pembrolizumab, another anti-PD-1 antibody, received accelerated approval in March 2017 for patients with cHL that is refractory or that has relapsed after ≥3 lines of therapy.
  • In patients with previously treated, CD30-positive cutaneous T-cell lymphoma, the ALCANZA trial compared brentuximab vedotin to physician’s choice of methotrexate or bexarotene. Brentuximab vedotin demonstrated a superior ORR4 (overall response rate lasting ≥4 months) compared with methotrexate or bexarotene (56% vs 12.5%; P < .0001).
  • The regulatory development of CAR-T cells continues, with tisagenlecleucel-T (also known as CTL019) currently under priority review for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. A second CAR-T cell therapy, axicabtagene ciloleucel (also known as KTE-C19), is in regulatory review for transplant-ineligible patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.

For additional commentary about this topic and others, visit www.gotoper.com to access downloadable slides from the 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma.





Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
3031
Filter By